ArticleProceedings of the National Academy of Sciences of the United States of America2003
Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Association between genetic variation of complement C3 and the susceptibility to advanced age-related macular degeneration: a meta-analysis.BMC ophthalmology · 2018Pooled it
- The Retinal Complications of C3 Dense Deposit Disease: A Scoping Review.Vision (Basel, Switzerland) · 2025Review
- Article
- Genetic Insights into Age-Related Macular Degeneration.Biomedicines · 2024Review
- Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Role of Adiponectin Peptide I (APNp1) in Age-Related Macular Degeneration.Biomolecules · 2022Article
- Novel therapies for proliferative retinopathies.Therapeutic advances in chronic disease · 2022Review
- Features of Retinal Neurogenesis as a Key Factor of Age-Related Neurodegeneration: Myth or Reality?International journal of molecular sciences · 2021Review
- Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye.International journal of molecular sciences · 2021Article
- Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer.Molecules (Basel, Switzerland) · 2020Review
- Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction.Frontiers in pharmacology · 2019Review
- Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.Cancer immunology research · 2018Article
- Rodent Models of Experimental Endometriosis: Identifying Mechanisms of Disease and Therapeutic Targets.Current women's health reviews · 2018Review
- Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases.Antibodies (Basel, Switzerland) · 2018Article
- Protection of tight junction between RPE cells with tissue factor targeting peptide.International journal of ophthalmology · 2018Article
- A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs.Investigative ophthalmology & visual science · 2017Article
- Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.Angiogenesis · 2017Article
- Article
- Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization.Investigative ophthalmology & visual science · 2015Article
- Roles of NFκB-miR-29s-MMP-2 circuitry in experimental choroidal neovascularization.Journal of neuroinflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness after age 55 in the industrialized world. Severe loss of central vision frequently occurs with the exudative (wet) form of AMD, as a result of the formation of a pathological choroidal neovasculature (CNV) that damages the macular region of the retina. We tested the effect of an immunotherapy procedure, which had been shown to destroy the pathological neovasculature in solid tumors, on the formation of laser-induced CNV in a mouse model simulating exudative AMD in humans. The procedure involves administering an Icon molecule that binds with high affinity and specificity to tissue factor (TF), resulting in the activation of a potent cytolytic immune response against cells expressing TF. The Icon binds selectively to TF on the vascular endothelium of a CNV in the mouse and pig models and also on the CNV of patients with exudative AMD. Here we show that the Icon dramatically reduces the frequency of CNV formation in the mouse model. After laser treatment to induce CNV formation, the mice were injected either with an adenoviral vector encoding the Icon, resulting in synthesis of the Icon by vector-infected mouse cells, or with the Icon protein. The route of injection was i.v. or intraocular. The efficacy of the Icon in preventing formation of laser-induced CNV depends on binding selectively to the CNV. Because the Icon binds selectively to the CNV in exudative AMD as well as to laser-induced CNV, the Icon might also be efficacious for treating patients with exudative AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.